Li-Wei Shao1, Yi Pan1, Xue-Ling Qi2, Yong-Xiao Li1, Xiao-Long Ma1, Wei-Ning Yi3, Jing Zhang4, Yan-Feng Zhong1, Qing Chang5. 1. Department of Pathology, School of Basic Medical Science, Peking University Third Hospital, Peking University, Beijing, China. 2. Department of Pathology, Beijing Sanbo Brain Hospital, Beijing, China. 3. Department of Epidemiology and Health Statistics, Peking University, Beijing, China. 4. Department of Pathology, School of Basic Medical Science, Peking University Third Hospital, Peking University, Beijing, China and Department of Neuropathology, Harborview Medical Center, University of Washington School of Medicine, Seattle, WA, USA. 5. Department of Pathology, School of Basic Medical Science, Peking University Third Hospital, Peking University, Beijing. China qingchang@bjmu.edu.cn.
Abstract
BACKGROUND: IDH1/2 mutation, 1p/19q-codeletion and MGMT hypermethylation are well known molecular markers for gliomas. ATRX and p53 alterations are two lineage-specific genetic aberrations in diffuse astrocytic tumors. The aim of the present study is to clarify the significance of ATRX loss and its correlation with p53 overexpression, IDH1/2 mutations, 1p/19q-codeletion and MGMT hypermethylation in supertentorial astrocytoma, and to determine the prognostic value of these factors in Chinese patients. METHODS AND RESULTS: A total of 135 adult supertentorial astrocytomas were evaluated. ATRX loss was detected by immunohistochemistry (IHC) and was shown to be much less frequent in pGBs (3.5%) than in grade II, III astrocytomas and IV sGBs (31%). Direct sequencing and/or IHC analysis of the IDH1R132H gene mutation and p53 accumulation demonstrated correlation with age. Strong correlations were found between ATRX loss and IDH1R132H mutation, p53 overexpression as well as MGMT hypermethylation. 1p/19q-codeletion detected by fluorescence in situ hybridization (FISH) showed mutually exclusive with ATRX loss and p53 accumulation. In addition, patients with p53 overexpression combined with ATRX alterations demonstrated substantially longer survival than patients with wild-type ATRX. CONCLUSIONS: There may be interactions among these distinct molecules in astrocytoma development. ATRX loss may predict better clinical outcome in astrocytoma patients with p53 overexpression as compared to patients with wild-type ATRX. Tumors with astrocytoma phenotype accompanied by 1p/19q-codeletion and IDH1R132H mutation are mutually exclusive with ATRX and p53 alterations. Routine IHC can be used for evaluation of ATRX loss, p53 protein accumulation and IDH1R132H mutation, which may allow a means of classification of astrocytoma outcome.
BACKGROUND:IDH1/2 mutation, 1p/19q-codeletion and MGMT hypermethylation are well known molecular markers for gliomas. ATRX and p53 alterations are two lineage-specific genetic aberrations in diffuse astrocytic tumors. The aim of the present study is to clarify the significance of ATRX loss and its correlation with p53 overexpression, IDH1/2 mutations, 1p/19q-codeletion and MGMT hypermethylation in supertentorial astrocytoma, and to determine the prognostic value of these factors in Chinese patients. METHODS AND RESULTS: A total of 135 adult supertentorial astrocytomas were evaluated. ATRX loss was detected by immunohistochemistry (IHC) and was shown to be much less frequent in pGBs (3.5%) than in grade II, III astrocytomas and IV sGBs (31%). Direct sequencing and/or IHC analysis of the IDH1R132H gene mutation and p53 accumulation demonstrated correlation with age. Strong correlations were found between ATRX loss and IDH1R132H mutation, p53 overexpression as well as MGMT hypermethylation. 1p/19q-codeletion detected by fluorescence in situ hybridization (FISH) showed mutually exclusive with ATRX loss and p53 accumulation. In addition, patients with p53 overexpression combined with ATRX alterations demonstrated substantially longer survival than patients with wild-type ATRX. CONCLUSIONS: There may be interactions among these distinct molecules in astrocytoma development. ATRX loss may predict better clinical outcome in astrocytomapatients with p53 overexpression as compared to patients with wild-type ATRX. Tumors with astrocytoma phenotype accompanied by 1p/19q-codeletion and IDH1R132H mutation are mutually exclusive with ATRX and p53 alterations. Routine IHC can be used for evaluation of ATRX loss, p53 protein accumulation and IDH1R132H mutation, which may allow a means of classification of astrocytoma outcome.
Authors: Elizabeth Scribner; James R Hackney; Hannah C Machemehl; Reina Afiouni; Krishna R Patel; Hassan M Fathallah-Shaykh Journal: J Neurooncol Date: 2017-04-27 Impact factor: 4.130
Authors: Daniel J Brat; Kenneth Aldape; Julia A Bridge; Peter Canoll; Howard Colman; Meera R Hameed; Brent T Harris; Eyas M Hattab; Jason T Huse; Robert B Jenkins; Dolores H Lopez-Terrada; William C McDonald; Fausto J Rodriguez; Lesley H Souter; Carol Colasacco; Nicole E Thomas; Michelle Hawks Yount; Martin J van den Bent; Arie Perry Journal: Arch Pathol Lab Med Date: 2022-05-01 Impact factor: 5.686
Authors: Alvaro Lassaletta; Michal Zapotocky; Eric Bouffet; Cynthia Hawkins; Uri Tabori Journal: Childs Nerv Syst Date: 2016-09-20 Impact factor: 1.475